ライフサイエンスコーパス: ErbB2 receptor

1 KCdelta disrupts association of Src with the ErbB2 receptor.

2 d interfered with trastuzumab binding to the ERBB2 receptor.

3 because of constitutive dimerization of the ErbB2 receptor.

4 lities including heterodimerization with the ErbB2 receptor.

5 ess a synthetic ligand-inducible form of the ErbB2 receptor.

6 or proliferative signaling downstream of the ErbB2 receptor.

7 f expression of oestrogen, progesterone, and ERBB2 receptors.

8 anization, i.e. collagen crosslinking and/or ErbB2 receptor activation.

9 at express a dominant-negative mutant of the ErbB2 receptor among oligodendrocytes, using an MBP prom

10 ErbB2 receptor and AKT were robustly phosphorylated in m

11 cFv induces downstream signaling through the ErbB2 receptor and H7 prevents transferrin binding to th

12 elated with decreased phosphorylation of the ErbB2 receptor and reduced activation of Src and MAPK/ER

13 ssion of activated (phosphorylated) EGFR and ERBB2 receptors and downstream signal intermediates were

14 We first showed that levels of erbB2 receptor are significantly decreased in an animal

15 CP-724,714 is a potent inhibitor of erbB2 receptor autophosphorylation in intact cells and i

16 he expression of estrogen, progesterone, and ERBB2 receptors) breast cancer cells.

17 ut not CCh, stimulated the formation of EGFR/ErbB2 receptor dimers and the recruitment of p85 to ErbB

18 uitment of the p85 subunit of PI3-K to ErbB3/ErbB2 receptor dimers, while the PI3-K inhibitor, wortma

19 r matrix, whereas cells devoid of functional ErbB2 receptors do not.

20 se expected changes in neuregulin levels and ErbB2 receptor expression after PNS injury were disrupte

21 The subsequent increase in erbB2 receptor expression makes the glia more responsive

22 BB3 receptors are apparently segregated from ERBB2 receptors in their resting state, and both ligand-

23 dose of compound reduced phosphorylation of ErbB2 receptors in tumor-bearing mice, demonstrating tar

24 We hypothesized that blockade of the erbB2 receptor induces cardiomyocyte death through a mit

25 The ErbB2 receptor is a clinically validated cancer target w

26 The Erbb2 receptor is activated by UV irradiation, the prima

27 Downregulation of the overexpressed 185-kDa ErbB2 receptor is rapidly (2-6 hours) induced by the HSP

28 Herceptin, an inhibitory antibody to the erbB2 receptor, is a potent chemotherapeutic but causes

29 , the contrasting effects of PS341 and GA on ErbB2 receptor localization, polyubiquitination, and deg

30 e expression of the NH2 terminally truncated ErbB2 receptor (p95ErbB2) in breast cancer correlates wi

31 Herein, the ErbB2 receptor pathway is inhibited with the selective m

32 onditioned media and neuregulin-1 stimulated erbB2 receptor phosphorylation in type II cells.

33 In the absence of GGF signaling via erbB2 receptors, radial glial development is abnormal.

34 Activation of the ErbB2 receptor signaling pathways can enhance various me

35 Protein levels of the full-length 185 kD ErbB2 receptor significantly decreased following NE trea

36 he two pathways in DCIS occurs regardless of ErbB2 receptor status and inhibition of Notch and ErbB1/

37 ibitors should be investigated regardless of ErbB2 receptor status.

38 PT/lapatinib or DAPT/gefitinib regardless of ErbB2 receptor status.

39 new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA

40 dhesion kinase, which occurs downstream from erbB2 receptor stimulation.

41 pothesized to interact with and activate the ErbB2 receptors, suggesting an intramembrane-growth fact

42 The ErbB2 receptor tyrosine kinase (RTK) is expressed in bas

43 rect bacterial ligation to and activation of ErbB2 receptor tyrosine kinase (RTK) signaling without E

44 In a mouse model of basal ErbB2 receptor tyrosine kinase 2 (ErbB2)-positive breast

45 nd metastasis, physically interacts with the ErbB2 receptor tyrosine kinase and augments receptor tyr

46 noma cell lines and associates with both the ErbB2 receptor tyrosine kinase and the LAR receptor tyro

47 Overexpression of the ERBB2 receptor tyrosine kinase and the mitochondrial inn

48 Deregulated Her2/ErbB2 receptor tyrosine kinase drives tumorigenesis and

49 The ErbB2 receptor tyrosine kinase is overexpressed in appro

50 The ErbB2 receptor tyrosine kinase plays a critical role in

51 ErbB2 receptor tyrosine kinase plays a role in neureguli

52 We hypothesized that ErbB2 receptor tyrosine kinase, a regulator of cancer ce

53 uregulin-1beta (NRG-1beta), a ligand for the erbB2 receptor tyrosine kinase, we hypothesized that act

54 , brain lipid binding protein (BLBP) and the erbB2 receptor tyrosine kinase.

55 at the cell cortex, acting downstream of the ErbB2 receptor tyrosine kinase.

56 epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases (RTKs).

57 have shown that forced overexpression of the ErbB2-receptor tyrosine kinase (RTK) promotes androgen-i

58 Inhibition of the ErbB2 receptor with Herceptin unexpectedly enhances nerv

59 gand-dependent activation of glial erbB4 and erbB2 receptors, without affecting erbB1 (EGF) receptor